Effects of Carbidopa/Levodopa/Entacapone on Motor Function and Quality of Life in Patients With Parkinson's Disease
Effects of Carbidopa/Levodopa/Entacapone on Motor Function and Quality of Life in Patients With Parkinson's Disease
To assess motor function and quality of life (QoL) in Parkinson's disease (PD) subjects with
 end-of-dose wearing off, comparing immediate and delayed switch to carbidopa/levodopa and
 entacapone.
This was a prospective, multi-center, randomized, open-label study with blinded raters to
 evaluate the effects of immediate versus delayed switch to carbidopa/levodopa/entacapone on
 motor function and quality of life in patients with Parkinson's disease with end-of-dose
 wearing off.
Inclusion Criteria:

 -  Males or females 30-80 years of age (inclusive). Patients aged 81-85 years were
 eligible to participate if the principal investigator considered the patient to be in
 otherwise good health.

 -  Clinical diagnosis of Parkinson's disease exhibiting two of three symptoms (rigidity,
 resting tremor, bradykinesia).

 -  All patients were required to have end-of dose wearing off (EODWO, re-emergence of PD
 symptoms at the end of at least two daily doses of levodopa during waking hours).

 -  Taking regular doses of immediate release carbidopa/levodopa

 Exclusion Criteria:

 -  Unstable Parkinson's Disease requiring booster doses or treatment with as needed dose
 regimens of levodopa

 -  Female subjects who are pregnant, trying to become pregnant or nursing an infant

 Other protocol-defined inclusion/exclusion criteria applied to this study.